title: Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy.
abstract: OBJECTIVE
  To compare pregnancy outcome prospectively after phenytoin and carbamazepine monotherapy with outcome in matched mother-child pairs exposed to nonteratogens to evaluate the relative fetal safety of these drugs.
  
  
  METHODS
  A prospective, controlled, and blinded observational study.
  
  
  METHODS
  Thirty-six mother-child pairs exposed to carbamazepine monotherapy and 34 pairs exposed to phenytoin monotherapy, all prospectively studied, were compared with mother-child pairs exposed to nonteratogens. The controls were matched for maternal age, time of consultation, obstetric history, and socioeconomic status.
  
  
  METHODS
  The primary end point of interest was the children's global IQ measured by either the Bayley or the McCarthy scale according to their ages.
  
  
  METHODS
  A teratology consultation program and two neurology services in Toronto, Ontario.
  
  
  RESULTS
  Children exposed to phenytoin in utero had a mean (+/- SD) global IQ 10 points lower (95% confidence interval, 4.9 to 15.8 points) than their matched controls (113.4 +/- 13.1 and 103.1 +/- 25.1; P = .038). The Reynell language development scores followed a similar trend, with children exposed to phenytoin scoring significantly lower than their controls. Phenytoin-exposed children had a global IQ of 84 or less significantly more often than the control group (P < .01). Children exposed in utero to carbamazepine did not differ from their controls on any of the neurobehavioral tests.
  
  
  CONCLUSIONS
  Our study suggests a clinically important negative effect of phenytoin on neurobehavioral development, independent of maternal or environmental factors, causing a substantial number of children to achieve a lower score than expected on cognitive tests. No similar effects could be shown after gestational use of carbamazepine.
authors.affiliation: Motherisk Program, Hospital for Sick Children, Toronto, Ontario, Canada.
authors.forename: D
authors.initials: D
authors.lastname: Scolnik
authors.forename: I
authors.initials: I
authors.lastname: Nulman
authors.forename: J
authors.initials: J
authors.lastname: Rovet
authors.forename: D
authors.initials: D
authors.lastname: Gladstone
authors.forename: D
authors.initials: D
authors.lastname: Czuchta
authors.forename: H A
authors.initials: HA
authors.lastname: Gardner
authors.forename: R
authors.initials: R
authors.lastname: Gladstone
authors.forename: P
authors.initials: P
authors.lastname: Ashby
authors.forename: R
authors.initials: R
authors.lastname: Weksberg
authors.forename: T
authors.initials: T
authors.lastname: Einarson
mesh_terms: D002220:Carbamazepine / Q000009:adverse effects* / Q000627:therapeutic use; D016022:Case-Control Studies; D002648:Child; D003071:Cognition / Q000187:drug effects*; D002658:Developmental Disabilities / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007361:Intelligence Tests; D008297:Male; D010672:Phenytoin / Q000009:adverse effects* / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D011256:Pregnancy Outcome; D011297:Prenatal Exposure Delayed Effects; D011446:Prospective Studies
chemical_list: D002220:Carbamazepine; D010672:Phenytoin